Get the Stockscreener App
1.93
3.02%
-0.06
Immuneering Corp stock is traded at $1.93, with a volume of 266.45K.
It is down -3.02% in the last 24 hours and down -18.22% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$1.99
Open:
$2
24h Volume:
266.45K
Relative Volume:
0.14
Market Cap:
$61.79M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-1.0212
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
-0.52%
1M Performance:
-18.22%
6M Performance:
+69.30%
1Y Performance:
-67.73%
1-Day Range:
$1.895
$2.02
1-Week Range:
$1.85
$2.10
52-Week Range:
$1.00
$7.68
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
1.93 | 61.79M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.12 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.55 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.40 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - Investing.com
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World
Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World
Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat
Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma
Wall Street-Heavily Traded - WDRB
Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks
Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Why Is Immuneering Stock Trading Higher On Tuesday? - AOL
Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News
Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl
Immuneering Corp reports promising clinical trial data - Investing.com India
Immuneering Surges Amid Promising Trial Data! What’s Driving the Surge? - Reporteros del Sur -
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - Markets Insider
Pre-Market Boost For Immuneering (IMRX) As Trial Data Impresses Investors - Stocks Telegraph
Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha
Immuneering stock soars on promising pancreatic cancer trial results By Investing.com - Investing.com South Africa
Immuneering stock soars on promising pancreatic cancer trial results - Investing.com India
Immuneering (IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - StreetInsider.com
Immuneering Announces Positive Data Update from Three - GlobeNewswire
Immuneering Co. (NASDAQ:IMRX) Sees Large Growth in Short Interest - MarketBeat
HighTower Advisors LLC Increases Stock Holdings in Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Forms Elite Advisory Board After FDA Fast Track Win for Pancreatic Cancer Drug - StockTitan
Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Average Price Target from Analysts - Defense World
IMRXImmuneering Corporation Latest Stock News & Market Updates - StockTitan
Immuneering to Present Key Clinical Data for IMM-1-104 Pancreatic Cancer Treatment in 2025 Investor Event - StockTitan
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schall Thomas J. | Director |
Mar 22 '24 |
Buy |
2.55 |
2,900 |
7,385 |
2,900 |
| Feinberg Peter | Director |
Mar 22 '24 |
Buy |
2.55 |
25,000 |
63,713 |
111,766 |
| Brakewood Harold Eugene | Chief Business Officer |
Mar 22 '24 |
Buy |
2.57 |
3,900 |
10,015 |
3,900 |
| Morales Mallory | Chief Accounting Officer |
Mar 21 '24 |
Buy |
2.72 |
1,107 |
3,009 |
7,885 |
| Morales Mallory | Chief Accounting Officer |
Mar 22 '24 |
Buy |
2.55 |
393 |
1,000 |
8,278 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Mar 20 '24 |
Buy |
2.88 |
3,818 |
10,993 |
10,029 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Mar 20 '24 |
Buy |
2.86 |
7,000 |
20,020 |
345,896 |
| BERMAN ANN E | Director |
Mar 18 '24 |
Buy |
2.13 |
57,965 |
123,436 |
67,465 |
| Feinberg Peter | Director |
Mar 18 '24 |
Buy |
2.38 |
50,000 |
119,058 |
61,766 |
| Feinberg Peter | Director |
Mar 19 '24 |
Buy |
2.56 |
25,000 |
64,000 |
86,766 |
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):